Screener
Agios Pharmaceuticals AGIO Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net cash provided by investing activities | 181,522 | 191,553 |
| Financing activities | ||
| Net proceeds from stock option exercises and employee stock purchase plan | 5,227 | 1,684 |
| Net cash provided by financing activities | 5,227 | 1,684 |
| Net change in cash and cash equivalents | 10,517 | 4,624 |
| Cash and cash equivalents at beginning of the period | 89,130 | 76,247 |
| Cash and cash equivalents at end of the period | $99,647 | $80,871 |
| Supplemental disclosure of non-cash investing and financing transactions |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's financing cash flow?
- Agios Pharmaceuticals (AGIO) reported financing cash flow of $3.15M in Q2 2026.
- How has Agios Pharmaceuticals's financing cash flow changed year-over-year?
- Agios Pharmaceuticals's financing cash flow increased by 4744.6% year-over-year, from $65K to $3.15M.
- What is the long-term trend for Agios Pharmaceuticals's financing cash flow?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's financing cash flow has grown at a -67.4% compound annual growth rate (CAGR), from -$765.77M to $8.68M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Agios Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude